Open AccessCurrent Clinical Psychopharmacology in Borderline Personality Disorder
Author(s) -
Antonio Del Casale,
Luca Bonanni,
Paride Bargagna,
Francesco Novelli,
Federica Fiaschè,
Marco Paolini,
Francesca Forcina,
Gaia Anibaldi,
Francesca Cortese,
Alessia Iannuccelli,
Barbara Adriani,
Roberto Brugnoli,
Paolo Girardi,
Joel Paris,
Maurizio Pompili
Publication year - 2021
Publication title -
current neuropharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.955
H-Index - 73
eISSN - 1875-6190
pISSN - 1570-159X
DOI - 10.2174/1570159x19666210610092958
Subject(s) - borderline personality disorder , mood , tolerability , medicine , anxiety , psychiatry , psychological intervention , psychopharmacology , clinical psychology , adverse effect
Patients with Borderline Personality Disorder (BPD) manifest affective and behavioral symptoms causing personal distress, relationship difficulties, and reduced quality of life with global functioning impairment, mainly when the disease takes an unfavorable course. A substantial amount of healthcare costs is dedicated to addressing these issues. Many BPD patients receive medications, mostly those who do not respond to psychological interventions.